| Model evaluation of continuous data pharmacometric models: metrics and graphics THT Nguyen, MS Mouksassi, N Holford, N Al‐Huniti, I Freedman, ... CPT: pharmacometrics & systems pharmacology 6 (2), 87-109, 2017 | 298 | 2017 |
| Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors M Centanni, DJAR Moes, IF Trocóniz, J Ciccolini, JGC van Hasselt Clinical pharmacokinetics 58, 835-857, 2019 | 274 | 2019 |
| Efficacy of 3, 4‐diaminopyridine and pyridostigmine in the treatment of Lambert–Eaton myasthenic syndrome: a randomized, double‐blind, placebo‐controlled, crossover study PW Wirtz, JJ Verschuuren, JG Van Dijk, ML De Kam, RC Schoemaker, ... Clinical Pharmacology & Therapeutics 86 (1), 44-48, 2009 | 136 | 2009 |
| A review of mathematical models for tumor dynamics and treatment resistance evolution of solid tumors A Yin, DJAR Moes, JGC van Hasselt, JJ Swen, HJ Guchelaar CPT: pharmacometrics & systems pharmacology 8 (10), 720-737, 2019 | 130 | 2019 |
| Integrating clinical metabolomics-based biomarker discovery and clinical pharmacology to enable precision medicine I Kohler, T Hankemeier, PH van der Graaf, CAJ Knibbe, JGC van Hasselt European journal of pharmaceutical sciences 109, S15-S21, 2017 | 96 | 2017 |
| Pharmacokinetics and clinical efficacy of phenobarbital in asphyxiated newborns treated with hypothermia: a thermopharmacological approach MPH Van Den Broek, F Groenendaal, MC Toet, HLM Van Straaten, ... Clinical pharmacokinetics 51, 671-679, 2012 | 95 | 2012 |
| Novel Δ9‐tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects LE Klumpers, TL Beumer, JGC van Hasselt, A Lipplaa, LB Karger, ... British Journal of Clinical Pharmacology, 2011 | 90 | 2011 |
| Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel JGC Van Hasselt, K Van Calsteren, L Heyns, S Han, MM Gziri, ... Annals of oncology 25 (10), 2059-2065, 2014 | 87 | 2014 |
| Predicting drug concentration‐time profiles in multiple CNS compartments using a comprehensive physiologically‐based pharmacokinetic model Y Yamamoto, PA Välitalo, DR Huntjens, JH Proost, A Vermeulen, ... CPT: pharmacometrics & systems pharmacology 6 (11), 765-777, 2017 | 77 | 2017 |
| Systematic evaluation of the descriptive and predictive performance of paediatric morphine population models EHJ Krekels, JGC van Hasselt, D Tibboel, M Danhof, CAJ Knibbe Pharmaceutical research 28, 797-811, 2011 | 76 | 2011 |
| Prediction of human CNS pharmacokinetics using a physiologically-based pharmacokinetic modeling approach Y Yamamoto, PA Välitalo, YC Wong, DR Huntjens, JH Proost, ... European Journal of Pharmaceutical Sciences 112, 168-179, 2018 | 74 | 2018 |
| A generic multi-compartmental CNS distribution model structure for 9 drugs allows prediction of human brain target site concentrations Y Yamamoto, PA Välitalo, DJ van den Berg, R Hartman, W van den Brink, ... Pharmaceutical research 34, 333-351, 2017 | 74 | 2017 |
| Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination YL Lo, JGC van Hasselt, SC Heng, CT Lim, TC Lee, BG Charles Antimicrobial Agents and Chemotherapy 54 (6), 2626-2632, 2010 | 72 | 2010 |
| Systems pharmacology: defining the interactions of drug combinations JGC Van Hasselt, R Iyengar Annual review of pharmacology and toxicology 59, 21-40, 2019 | 69 | 2019 |
| Effects of antibiotic resistance, drug target attainment, bacterial pathogenicity and virulence, and antibiotic access and affordability on outcomes in neonatal sepsis: an … KM Thomson, C Dyer, F Liu, K Sands, E Portal, MJ Carvalho, M Barrell, ... The Lancet Infectious Diseases 21 (12), 1677-1688, 2021 | 65 | 2021 |
| A comparison of mRNA sequencing with random primed and 3′-directed libraries Y Xiong, M Soumillon, J Wu, J Hansen, B Hu, JG Van Hasselt, ... Scientific reports 7 (1), 14626, 2017 | 62 | 2017 |
| Pronounced between‐subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers BAW Jacobs, MJ Deenen, D Pluim, JGC van Hasselt, MD Krähenbühl, ... British Journal of Clinical Pharmacology 82 (3), 706-716, 2016 | 61 | 2016 |
| Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer … D Meulendijks, JGC van Hasselt, ADR Huitema, H van Tinteren, ... European Journal of Cancer 54, 120-130, 2016 | 61 | 2016 |
| Disruption of podocyte cytoskeletal biomechanics by dasatinib leads to nephrotoxicity RC Calizo, S Bhattacharya, JGC van Hasselt, C Wei, JS Wong, RJ Wiener, ... Nature communications 10 (1), 2061, 2019 | 59 | 2019 |
| Pharmacokinetic–pharmacodynamic relationships of central nervous system effects of scopolamine in healthy subjects M Liem‐Moolenaar, P de Boer, M Timmers, RC Schoemaker, ... British journal of clinical pharmacology 71 (6), 886-898, 2011 | 57 | 2011 |
Catherijne A.J. KnibbeProfessor of Individualized Drug Treatment, Leiden UniversityGeverifieerd e-mailadres voor antoniusziekenhuis.nl
